Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) will support the development of collaborative research projects to establish a set of complementary model systems that reproduce essential disease-defining features of human idiopathic pulmonary fibrosis (IPF). The purpose of this initiative is to unify a series of projects encompassing multiple complementary model systems that each effectively reproduces essential disease features of human IPF. This FOA encourages applications to develop research models that will advance our understanding of the pathogenesis of IPF from its onset through disease progression and serve as a resource for the broader research community including investigators testing novel therapies to treat this disease.


  • Letter of Intent Due Date(s): September 1, 2019
  • Application Due Date(s): October 1, 2019

RFA-HL-20-007 Expiration Date October 2, 2019

Agency Website

Amount Description

Application budgets may not exceed $300,000 direct costs in FY2020 and may not exceed $400,000 in direct costs in FY2021 through FY2023.

Administrative Coordinating Center (ACC) - an additional $80,000 in direct costs in FY2020 and $100,000 in direct costs in FY2021, FY2022, and FY2023 will be available for one site selected to serve as the ACC for the entire program.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

October 1, 2019